Atea Pharmaceuticals, Inc. — Q2 2022 Form 10-Q Summary
Business Context and Reporting Period
Atea is a clinical-stage biopharmaceutical company developing antiviral therapeutics for COVID-19, dengue, hepatitis C, and respiratory syncytial virus. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. Atea had 83.3 million common shares outstanding as of June 30, 2022 and 63 full-time employees as of August 1, 2022.
Financial Highlights
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Collaboration revenue | $0 million vs. $60.4 million | $0 million vs. $126.4 million |
| Research and development expense | $19.9 million vs. $39.8 million | $49.5 million vs. $66.4 million |
| General and administrative expense | $12.4 million vs. $11.9 million | $25.0 million vs. $20.7 million |
| Total operating expenses | $32.3 million vs. $51.7 million | $74.5 million vs. $87.0 million |
| Net income (loss) | $(31.3) million vs. $1.5 million | $(73.4) million vs. $32.3 million |
| Net income (loss) per share, basic | $(0.38) vs. $0.02 | $(0.88) vs. $0.39 |
| Net cash used in operating activities | Not separately provided | $(78.2) million vs. $(34.2) million |
There was no product revenue. Revenue in the prior-year periods consisted of Roche collaboration revenue. Operating and net margins were not meaningful in the current period because revenue was zero. Interest income and other, net was $1.1 million for the quarter and $1.2 million for the six months, primarily reflecting higher interest rates.
Cash and cash equivalents were $684.5 million at June 30, 2022, including $657.9 million in money market funds. Cash, cash equivalents and restricted cash declined by $79.9 million during the first six months. Investing cash use was $1.9 million for property and equipment, while financing cash provided was $0.2 million from stock-option exercises.
No debt was reported. Operating lease liabilities totaled $3.5 million, including $0.7 million current and $2.8 million noncurrent. Total liabilities were $33.9 million, and stockholders’ equity was $660.5 million.
Material Changes Versus the Prior Comparable Period
- Collaboration revenue fell to zero following Roche’s termination of the license agreement, effective February 10, 2022. Atea recognized the remaining deferred Roche revenue in 2021.
- Atea regained worldwide rights to bemnifosbuvir but became solely responsible for related development costs. The reduction in research and development expense primarily reflected the absence of Roche cost-sharing activity.
- Six-month net income of $32.3 million in 2021 changed to a net loss of $73.4 million in 2022.
- Six-month general and administrative expense increased $4.3 million, primarily from higher payroll, personnel, and stock-based compensation costs.
- Stock-based compensation increased to $23.6 million from $17.3 million for the six-month period.
- Accrued expenses declined to $10.5 million from $52.2 million at year-end 2021, primarily because the $25.0 million license fee accrual and other obligations were reduced or paid. Accounts payable increased to $13.9 million from $4.5 million.
Clinical Development, Outlook, and Risks
- Bemnifosbuvir/COVID-19: The MORNINGSKY Phase 3 trial did not achieve its primary endpoint of time to symptom alleviation. Management reported an exploratory 71% reduction in hospitalization, 2.9% versus 10.0% for bemnifosbuvir versus placebo, with no deaths; the trial enrolled 207 evaluable patients and was closed early.
- In a Phase 2 hospitalized study, progression of respiratory insufficiency was 7.5% versus 10.0% for placebo, with three deaths in the placebo group and none in the bemnifosbuvir group. The sample size was insufficient for statistical comparisons.
- Following July 2022 discussions with the FDA and EMA, Atea expected to finalize a global late-stage trial protocol focused on high-risk mild-to-moderate COVID-19 patients, including immunocompromised patients, with initiation targeted for the fourth quarter of 2022.
- Atea was also advancing a second-generation protease inhibitor intended for combination therapy, with clinical-candidate selection targeted for late 2022.
- HCV: Atea was preparing a Phase 2 combination study of bemnifosbuvir and Merck-licensed ruzasvir and was manufacturing clinical supplies.
- Dengue: The DEFEND-2 global Phase 2 study of AT-752 had begun, along with a U.S. dengue human-challenge trial.
- Management expected research and development spending to increase substantially as it advances COVID-19, dengue, HCV, RSV, manufacturing, regulatory, and potential commercialization activities.
- Atea stated that its cash and cash equivalents were expected to fund planned operations through at least 2025 under its current operating plan. The filing also states that cash was sufficient for at least twelve months from issuance, but additional capital will ultimately be required.
- A $200 million at-the-market equity facility was available, but no shares had been issued under it as of June 30, 2022. Future equity or debt financing could dilute stockholders, restrict operations, or require unfavorable terms.
Key Risks, Contingencies, and Unusual Items
- Atea has no approved products, no commercial product revenue, and expects continuing operating losses and cash use.
- Clinical results are subject to uncertainty, including the failure of the MORNINGSKY primary endpoint, prior failure of the MOONSONG Phase 2 primary endpoint, small sample sizes, evolving COVID-19 variants, changing standards of care, and competition from authorized or approved therapies such as Paxlovid and molnupiravir.
- The company relies substantially on third-party CROs and CMOs, including sole suppliers in China for active pharmaceutical ingredients, and does not have long-term supply agreements for these components.
- An Indian pre-grant opposition challenges pending patent claims covering AT-511/bemnifosbuvir and its HCV use. The proceeding may take several years and could prevent patent issuance in India.
- A consultant success fee of up to $5.0 million is contingent on future product sales; the timing and likelihood were not probable or estimable.
- Atea reported no material legal proceedings, and management concluded that disclosure controls and procedures were effective as of June 30, 2022.
Investor Verification Checklist
- Verify the design, timing, enrollment, and regulatory feedback for the planned late-stage bemnifosbuvir COVID-19 trial.
- Assess whether the exploratory hospitalization findings remain supportive in final, audited datasets and whether regulators accept the proposed development strategy.
- Track quarterly cash burn, research and development commitments, and the duration of the stated cash runway.
- Monitor potential use of the $200 million equity facility and the resulting dilution risk.
- Review progress and financing needs for the ruzasvir HCV program, AT-752 dengue trials, and the protease-inhibitor program.
- Follow the Indian patent opposition and broader patent protection for bemnifosbuvir and related technologies.
- Confirm manufacturing readiness and supply continuity, particularly for ruzasvir and components sourced from China.